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Summary
The effects of transforming growth factor a (TGF-a) on interferon y-mediated killing of the
intracellular protozoan parasite Trypanosoma cruzi and on the course of T . cruzi infection in mice
were investigated. Spleen cells from mice with acute T . cruzi infections were found to produce
elevated levels ofbiologically active TGF-0 in vitro, and the possibility that TGF-0 may mediate
certain aspects of T . cruzi infection was then addressed . When mouse peritoneal macrophages
were treated with TGF-0 in vitro, the ability of IFN-y to activate intracellular inhibition of
the parasite was blocked. This occurred whether cells were treated with TGF-0 either before
or after IFN-y treatment . TGF-0 treatment also blocked the T . cruzi-inhibiting effects ofIFN-y
on human macrophages. Additionally, treatment ofhuman macrophages with TGF-0 alone led
to increased parasite replication in these cells . The effects ofTGF-0 on T . cruzi infection in vivo
were then investigated . Susceptible C57BL/6 mice developed higher parasitemias and died earlier
when treated with TGF-0 during the course of infection . Resistant C57BL/6 x DBA/2 F1
mice treated with TGF-0 also had increased parasitemias, and 50% mortality, compared with
no mortality in infected, saline-treated controls. A single dose ofTGF-R, given at the time of
infection, was sufficient to significantly decrease resistance to infection in F1 mice and to exacerbate
infection in susceptible C57BL/6 mice . Furthermore, a single injection ofTGF-0 was sufficient
to counter the in vivo protective effects ofIFN-y . We conclude that TGF-/3, produced during
acute T . cruzi infection in mice, is a potent inhibitor of the effects of macrophage activating
cytokines in vivo and in vitro and may play a role in regulating infection .
T
he hemoflagellate protozoan Trypanosoma cruzi causes
Chagas' disease, a major public health problem in many
countries of Latin America. Infection with this parasitemay
be acute or chronic, and frequently involves the development
of progressive pathology in tissues of the heart, esophagus
and colon . In vitro and in vivo, the parasites infect a variety
of nucleated cells, including macrophages . In both humans
and laboratory animals, T . cruzi infection is accompanied by
a nonspecificimmune depression mediated byT cells and mac-
rophages which results in reduced T cell function, including
help for antibody production (1) and cytotoxicity (2) .Tcells
from infected micemay have reduced capacity to produce 11,2
and display IL2R (3). Several cytokines have been shown to
reverse depressed immune function in infected mice, including
I1r2 (4-6), 11A (7), and granulocyte macrophage colony-
stimulating factor (GM-CSF)' (8) . Evidence has been pre-
1 Abbreviation used in this paper . GM-CSF, granulocyte macrophage colony-
stimulating factor.
sented that IL1 and GM-CSF may function at least in part
by restoring or increasing IL2production in infected animals
(7, 8) .
The mechanisms which control parasite replication during
the acute and chronic phases and which maintain low but
persistent numbers of circulating parasites during the chronic
phase are not well understood, but both T cell cytokines and
lytic antibodies appear to be involved . Among cytokines,
IFN-y has a remarkable capacity to activate macrophages and
inhibit the replication of T . cruzi both in vitro (9, 10) and
in vivo (11) . IFN-y appears to have an important role in the
very early stage of T cruzi infection in determining disease
outcome (11) . Endogenous IFN-y is important in control-
ling T . cruzi infection since treatment with anti-IFN-ymAb
rendered resistant mice susceptible to acute disease (Silva, J.S.,
P.J. Morrissey, K.H . Grabstein, K.M. Mohler, and S.G. Reed,
manuscript submitted for publication) .
Thus cytokines play key roles in regulating both parasite
replication and immune responses in infected animals. One
cytokine which is associated with both immune regulation
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protein is produced by many cells including B, T, and acti-
vated macrophages (12-14) and hasbeen implicated as amedi-
ator of immunosuppression, inhibiting IL-2 receptor induc-
tion (14), ILA induced thymocyte proliferation (15), B cell
proliferation and differentiation (12), IFN-y induced class II
antigen expression (16), cytotoxic lymphocyte generation, and
lymphokine activated killer cells (17) . In addition, TGF-(3
has the ability to inhibit cytokine-induced macrophage acti-
vation (18), suppressing the production of reactive oxygen
and nitrogen intermediates (18, 19) . The potent effects of
TGF-0 on cellular immune responsesresemble inmany ways
those accompanying acute T . cruzi infection. In the present
report, we have evaluated the effects ofTGF-0 on experimental
T . cruzi infection, both in vitro and in vivo, and present evi-
dence for the involvement ofTGF-0 in parasite survival and
the production of fatal infections .
Materials and Methods
Mice .
￿
6-8-wk-old female BALB/c, C57BL/6, (B6), and (C57-
BL/6 x DBA)F1(B6D2) mice were obtained fromJackson Labora-
tories (Bar Harbor, ME) .
Parasite.
￿
A clone of the Tulahuen strain of T . cruzi, designated
as MHOM/CH/00/Tulahuen C2, was used in all experiments .
Trypomastigotes were grown in the L6E9 rat myoblast cell line
and used to infect mice by i.p. injection of 10 3 parasites in 0.2 ml
of PBS, or s.c. injection in the footpad in 0.02 ml . T . cruzi
trypomastigote lysate was used at 10Rg protein/ml and consisted
of freeze-thawed trypomastigotes centrifuged at 10,000 g for 30
min and filtered through a 0.22 Am filter.
Cytokines. rMu-IFN-y (5.2 x 106 U per mg protein) and
rHu-IFN-y (101 U per mg protein) was provided by Genentech,
Inc. (San Francisco, CA) as protein purified to homogeneity from
Escherichia coli. Human TGF-0 was purchased from Calbiochem
Corp . (La Jolla, CA) and rMu-TGF-(3 was a gift from Genen-
tech, Inc.
Macrophages .
￿
Mouse macrophages were harvested from peri-
toneal cavities 3-5 d after injection of 1 ml of6% sodium caseinate
(Eastman Kodak Company, Rochester, NY). The cells were har-
vested with cold RPMI 1640 (Gibco Laboratories, Grand Island,
NY)washed, and plated on the 12 mm round coverslips in 24-well
plates (5 x 10 5 cells/well) or directly into 48-well plates (2.5 x
105 cells/well). After 2 h at 37°Cin 5% CO Z , adhered cells were
washed with warm PBS and cultured in RPMI/5% endotoxin-
freeFCS (Cellect Gold, Flow Labs, McLean, VA) plus antibiotics .
Human macrophages were obtained from normal donor PBMC
(AmericanRed Cross, Portland,OR) purified on Percoll gradients
and cultured for 5 d in RPMI/5% human AB serum.
Microbicidal Activity.
￿
Mouse or human macrophages were in-
cubatedwith or without TGF-0and/or IFN-y for48 h. Cellswere
washed and infected at a parasite:cell ratio of 1:1 for 2 h at 37°C .
Extracellular parasites were removed by three washes with RPMI
and the cells incubated for the indicated times in the presence or
absence of cytokine. The growth of parasites in macrophages was
evaluated by counting trypomastigotes released at various times
after infection and by counting intracellular amastigotes as de-
scribed (20) .
Transforming Growth Factor /3 Bioassay.
￿
Production of active
TGF-awasdetermined as described (21) . Themink lung epithelial
cell line CCL64 was plated in 96-well tissue culture plates at 3.5
x 103 cells per 50 Fl of DMEM containing 10% FCS. Superna-
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tant from spleen cell cultures from uninfected or T . cruzi infected
mice were incubated at 5 x 106 cells/ml in RPMI + 5% FCS
(bothendotoxin free) for 48 h in the presence or absence ofT . cruzi
lysate at 37°C and assayed for TGF-0 activity. Samples were added
to triplicate wells 5 h after plating ofcells. After incubation at 370C
for 72 h'a'I-IodoUdr (M 355 ; Amersham, Arlington Heights, IL;
1 p,Ci/ml) was added and the cells were incubated an additional
24 h. Inhibition of growth was expressed in the percent decrease
of 'ZSI-IodoUdr incorporation in treated cells when compared to
incorporation in untreated cells. A standard curve with human
platelet TGF-/31 (0.05-10 ng/ml) was run in each assay. The
specificity of this bioassay has been demonstrated, including inhi-
bition of the assay by monoclonal antiTGF-(3 antibody (22) .
Statistics .
￿
Student's t test was used to analyze data .
Results
Production of Transforming Growth Factor 0 by Spleen Cells
from Mice Infected with T . cruzi. Experimental T . cruzi infec-
tion is associated with a profound and lasting depression of
spleen cell immune responsiveness (1, 4-8) . Because of the
association ofTGF-0 with immune suppression, we looked
for production of this cytokine by spleens of infected mice.
The production of active TGF-0 by mouse spleen cells was
determined using a sensitive growth inhibition assay. Fig . 1
showsTGF-0production by spleen cellsfrom uninfected mice
and from mice at different time points after infection. In-
creasing amounts of activeTGF-0were produced and released
by cells taken during the course of acute infection. Levels of
TGF-0 were significantly elevated by8d after infection. Cells
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Figure 1 .
￿
Production ofactive TGF-0 by spleen cells from mice infected
with T . cruzi. Spleen cells from B6 mice obtained at different days after
infection with 103 trypomastigotes of T . cruzi were incubated for 48 h
in thepresence (0) or absence (O) of trypomastigote lysate, and superna-
tants were tested forbiologically active TGF-0 . The first points (0 d) indi-
cate uninfected control mice .incubated in the presence ofparasite lysate produced the same
amounts of TGF-)3 as those incubated in medium alone. Of
particular interest was that detection of active TGF-# did not
require prior acidification. This indicated that the cells were
producing the active form of TGF-0, and suggested that ac-
tivation occurred within the spleen cells.
Effects of TGF-O on IFN-y-Induced Inhibition of T . cruzi in
Macrophages. We and others have associated cytokine-induced
inhibition of T. cruzi in macrophages with enhanced oxida-
tive metabolism (20, 23). One of the molecules shown to
decrease macrophage ability to respond to cytokine with in-
creased oxidative metabolism is TGF-(3 (18). Therefore we
first examined the in vitro effects of TGF-0 on the ability
of mouse or human macrophages to inhibit intracellular repli-
cation of T. cruzi following activation with IFN-y. Mouse
peritoneal macrophages were treated with TGF-13 or IFN-y
48 h before or 2 h after infection. Numbers of extracellular
trypomastigotes released from the cells were determined 5 d
later. Pre- or post-infection treatment with 10 U of murine
rIFN-y significantly inhibited T. cruzi replication. The de-
gree of inhibition was less than we have previously reported
(11) due to the lower amount of IFN-y used in the present
study, but either pre- or post-treatment of macrophages led
to 70-75% fewer parasites released from the cells (Table 1).
However, treatment of the macrophages with TGF-0 48 h
before infection prevented the inhibition of parasite replica-
tion by IFN-y. Whereas IFN-y treatment 2 h after infection
led to an approximately 70% reduction in parasite liberation
(Table 1, group 4), prior incubation with TGF-a prevented
this inhibition (group 7). Similarly, whereas a 48 h preincu-
bation ofmacrophages in IFN-y led to a 76% inhibition of
parasites (group 2), post-infection treatment of the IFN-
y-treated cells with TGF-R eliminated the parasite inhibi-
tion (group 6). Pre- or post-treatment with TGF-a alone had
little effect on parasite numbers in this system. In another
Cytokines added
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series of experiments, mouse peritoneal macrophages were
treated with different doses of IFN-y before infection with
T . cruzi, in the presence or absence of TGF-0 (Fig. 2). Con-
centrations of 10 and 100 U IFN-y/ml inhibited both intra-
cellular amastigotes (Fig. 2 A) and the liberation of extracel-
lular trypomastigotes (Fig. 2 B). Post- and or pre-infection
treatment with TGF-a significantly inhibited the effects of
IFN-y at all doses tested. Together, these experiments (Table
1, Fig. 2) demonstrate that the IFN-y-mediated inhibition
of T. cruzi in mouse peritoneal macrophages is blocked by
TGF-0.
Further experiments examined the effect of TGF-(3 on the
inhibition of T. cruziby human macrophages. Peripheral blood
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Figure 2.
￿
Effects of TGF-0 on inhibition of T . nuzi development in
mouse peritoneal macrophages in vitro. The cells were plated on 13 mm'
round glass coverslips (A) or 48 well plates (B) and incubated for 24 h
with the indicated concentration of rMuIFN-y without (O), or with 1 ng/
ml rMuTGF-0 before ("), or before and after (21) infection with T. cruzi.
(A) Coverslips were fixed 48 h after infection, and numbers ofamastigotes
per 100 macrophages determined. (B) Extracellular trypomastigotes were
counted 5 d after infection. Points represent z ± SD.
Table 1.
￿
Transforming Growth Factor ,!3 Blocks the Interferon y-mediated Inhibition of T. cruzi in Cultured Mouse Macrophages'
100
Peritoneal macrophages were treated with rIFN-,y (10 U/ml) or TGF-/3 (1 ng/ml) as indicated. Cells were infected with T. cruzi trypomastigotes,
washed thoroughly after 2 h to remove extracellular parasites, and incubated with the indicated cytokines. After 5 d, extracellular trypomastigotes
were counted. Groups 2 and 4 vs. groups 1, 3, 5, 6, 7, p < 0.05.
Group
48 h before
infection
2 h after
infection No. trypomastigotes/p,l
x±SD
% Inhibition
1 - - 356 ± 32
2 IFN-.y - 87 ± 15 76
3 TNF-a - 400 ± 28 -12
4 - IFN-y 113 ± 12 68
5 - TGF-/3 293 ± 15 18
6 IFN-y TGF-/3 307 ± 25 14
7 TGF-(3 IFN-y 380 ± 28 -7monocytes were adhered to 12 mm round glass coverslips for
5 d before treatment with TGF-(3 and/or IFN--y . 48 h later,
the macrophages were infected with T, cruzi, and numbers
of intracellular amastigotes were determined after 72 h . Data
from four individual donors are shown in Table 2 . As was
seen with mouse macrophages, treatment with TGF-a blocked
the IFN-y-mediated inhibition of parasite replication. Pre-
or post-infection treatment withIFN-y significantly reduced
Table 2 .
￿
Transforming Growth Factor ,B Exacerbates In Vitro T . cruzi Infection in Human Macrophages and Blocks the Effects
of Interferon y
.
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the replication of T, cruzi in human macrophages as previ-
ously described (20) . Treatment of the macrophages with
TGF-(3 either before or after the addition ofIFN-y inhibited
this effect . In addition, treatment with TGF-a alone, either
before or after infection of the cells, led to a significant in-
crease in intracellular parasite numbers. This demonstrated
thatTGF-O treatment exacerbated T . cruzi infection in normal
human macrophages .
" PBMC-derived macrophages were treated with TGF-(3 (1 ng/ml) or rIFN-y (100 U/ml) 48 hbefore or 2h after infection with T . cruxi trypomastigotes .
Number of intracellular amastigotes determined 72 h after infection . In all donors, groups 4 vs . 6, and 2 vs . 7, p 4 0.05 .
Group
Donor 1
TGF-a
Before After
IFN--y
Before After Amastigotes/100 cells
x±SD
% Inhibition
1 - - - - 246 ± 16
2 - - + - 110 ± 25 55
3 + - - - 365 ± 76 -48
4 - - - + 55 t 6 78
5 - + - - 411 ± 27 -67
6 + - - + 264 ± 38 -7
7 - + + - 220 ± 23 11
Donor 2
1 - - - - 265 ± 3 -
2 - - + - 76 ± 23 71
3 + - - - 295 ± 19 -11
4 - - - + 116 ± 6 56
5 - + - - 434 ± 94 -64
6 + - - + 263 ± 46 1
7 - + + - 274 ± 90 -3
Donor 3
1 - - - - 247 ± 29 -
2 - - + - 124 ± 13 50
3 + - - - 384 ± 47 -55
4 - - - + 195 ± 29 21
5 - + - - 385 ± 59 -56
6 + - - + 279 ± 31 -13
7 - + + - 276 ± 74 -12
Donor 4
1 - - - - 297 ± 103 -
2 - - + - 139 ± 33 53
3 + - - - 508 ± 88 -71
4 - - - + 131 ± 55 56
5 - + - - 549 ± 57 -85
6 + - - + 303 ± 24 -2
7 - + + - 231 ± 46 22Effects of Transforming Growth Factor-# on T . cruzi Infection
In Viva In vitro, TGF-(3 treatment blocked inhibition of
T . cruzi mediated by IFN-y and, in some cases, exacerbated
intramacrophage replication ofthe parasite. We therefore ex-
amined the effects oftreatment of mice with TGF-fl on T . cruzi
infection . We have developed a model to examine parameters
of resistance and susceptibility to T . cruzi . B(B6)6 mice are
extremely susceptible to the Tulahuen strain of T . cruzi,
resulting in 100% mortality following infection with as few
as 50 blood forms . B6D2 mice, however, are highly resistant
to this organism, with 100% survival resulting from infec-
tion with as many as 105 parasites. To examine the effects
of TGF-/3 on the course of infection in resistant and suscep-
tible mice, B6 and B6D2 were injected with TGF-a, 1 d be-
fore infection, and at multiple d after infection with 10 3
T . cruzi . The results are shown in Fig. 3 . In B6 mice, TGF-a
treatment led to parasitemias which were significantly higher
than in saline-treated mice, with an accompanying decrease
in survival time . Similarly, a striking increase in parasitemia
and mortality was seen in B6D2 mice treated with TGF-(3 .
Whereas none of the saline treated mice died, 50% of the
TGF-0-treated mice died by 20 d after infection .
The in vivo effects of TGF-/3 administration on infection
with T . cruzi were confirmed in experiments in which sus-
ceptible B6 mice were infected s.c. in the footpad. This infec-
tion route produced a lower parasitemia and mortality rate
than i.p. infection . In these experiments, illustrated in Fig.
4, mice were given a single s .c. injection of 1 Ag ofrMuTGF-Q
(or saline) at the time of infection . As was observed with
i.p. infection experiments, treatment with TGF-a led to
significantly increased parasitemias and mortalities in B6 mice.
TGF-a-treatment also eliminated the in vivo protective effect
ofIFN- ,y on T . cruzi infection (11) . Thus, in vivo results cor-
Figure 3 .
￿
Effects ofTGF-/3 on the course ofT . cruzi infection in resis-
tant (B6D2) and susceptible (B6) mice. The B6D2 (O) or B6 mice (A)
were treated i.p. with PBS (opened symbols) or 10 Ag ofrMuTGF-0 (closed
symbols) on -1, 0, 2, 5, and 9 d after i.p. infection with 103 trypomasti-
gotes . Points represent the mean ± SEM of 6 mice . At 10, 12, 15, 18,
20 and 22 d, TGF-,B treated vs . control, p < 0.05 for both mouse strains .
Inset shows cumulative mortality on d 20 after infection in PBS (black
bar) or TGF-0 (grey bar) treated mice.
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Figure 4.
￿
TGF-/3 inhibits the effects ofIFN-,y in vivo, Susceptible (B6)
mice were infected sc in the footpad with 103 trypomastigotes in PBS only
(O), or PBS containing 1 wg ofrMuTGF-,B ("), 2 iug ofrMuIFN-y (A),
or both 1 kg of rMuTGF-0 and 2 ttg ofrMuIFN-y ("). Points represent
mean ± SEM of 6 mice. At 16, 18, and 22 d, mice treated with IFN-,y
(0) vs. mice treated with IFN-y + TGF-b (" ), p < 0.05 . Inset shows
cumulative mortality on d 28 after infection in mice treated with saline
(black bar), IFN- ,y (stippled bar), TGF-0 (white bar) or both TGF-Q and
IFN (cross-hatched bar). Mice treated with IFN-y vs. other groups, p < 0.05 .
roborated those obtained in vitro. Mice treated with TGF-/3
had exacerbated infections as well as an inhibition ofthe ther-
apeutic effect of IFN- ,y treatment .
Discussion
The macrophage is a pivotal cell in the host immune re-
sponse to T . cruzi. During the very early stages of infection
the parasites are found within macrophages, which may in-
hibit their replication or provide a favorable environment in
which T . cruzi can multiply and be disseminated . Evidence
for the importance of macrophage activity in determining
the outcome ofinfection comes largely frofn experiments done
in vivo which demonstrated that early treatment with rIFN-y
can reverse the course of fatal infection (11) . Thus mice treated
with rIFN-y beginning within 24 h after infection had 100%
survival, vs . 100% mortality in saline-treated mice or in mice
treated with IFN-y 7 d after infection . Further, a single dose
of neutralizing antibody to IFN-y, given within 24 h after
infection, is sufficient to produce fatal infections in resistant
B6D2 mice, as well as significantly exacerbate infections in
susceptible B6 mice (Silva, J.S., P.J . Morrissey,K.H . Grab-
stein, K.M. Mohler, and S.G . Reed, manuscript submitted
for publication), providing evidence for the importance of
physiological levels of endogenous IFN-y . The macrophage
is the most likely target for the dramatic effects of IFN-y,
suggesting that severity of infection with T . cruzi depends
significantly upon how effectively these phagocytic host cells
limit early parasite replication .
In vitro, mouse macrophages activated by IFN- ,y are very
effective at limiting T . cruzi replication (20) . This activityhas been associated, at least in part, with increased oxidative
metabolism resulting from cytokine stimulation (20, 23). One
of the described effects of TGF-0 on macrophage function
is the down regulation of oxidative metabolism (18). Results
in the present studyindicated that TGF-0 could both increase
intea-macrophage replication of T. cruzi as well as block the
inhibitory effect of IFN-.y . These findings support the im-
portance of reactive oxygen intermediates in the intramac-
rophage inhibition of T. cruzi.
It is apparent from this and other studies that cytokines
play a variety of crucial regulatory roles in the host response
to parasites. They are also essential in regulating host responses
not directed at the parasite. Several cytokines, including IL-2
(5, 6), IL1 (7), and GM-CSF (8), have been shown to have
the capacity ofrestoring immunological competence to spleen
cells from infected mice. At least three cytokines, IFN-y, GM-
CSF, and TNF (20, 24) have been shown to have the capacity
to limit replication of T. cruzi in macrophages. The present
report demonstrates that another cytokine, TGF-(3, is pro-
duced during T. cruzi infection, and has the potential of al-
tering the course of that infection. At least one of the ways
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